AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research ... from AnaptysBio’s Phase 2b study of ANB032 for atopic dermatitis, which failed to ...

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock ...

On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist ...

(RTTNews) - Shares of AnaptysBio, Inc. (ANAB) are down over 30% as the clinical-stage biotechnology company announced that its Phase 2b trial of ANB032 in Atopic Dermatitis did not meet the ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist ...

ANB032 failed to meet primary and secondary endpoints in a Phase 2 trial for moderate-to-severe atopic dermatitis (AD). AnaptysBio will shift resources to autoimmune programs with key trial data ...

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock, ...

On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial ...